AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06260423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experienced dentist using Single cone with bioceramic sealer.
Description: Root canal treatment using bioceramic sealers.
Study NCT06260423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unexperienced dentist using Single cone with bioceramic sealer.
Description: Root canal treatment using bioceramic sealers.
Study NCT06444256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVO
Description: Participants will receive 20mg of SUVO for 7 days in the evening before bed on Day 5 through Day 11
Study NCT06444256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAU
Description: Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.
Study NCT06444256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.
Study NCT06371495 — intervention group
Intervention type: DRUG
Intervention: rosuvastatin
Description: Stude include three groupsof people GroupA: recieve rosuvastatin 40mg Group B :recive rosuvastatin 20mg Group C: recive placebo 2- Follow up will be done using NIHSS at the onset and modified Rankin scale at the onset and after 1 month and 3 months of the onset.~3- Carotid duplex will be done at the onset and after 1 month and 3 months of the onset.
Study NCT05924425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Description: Patients randomized in the experimental group will receive the treatment every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
Study NCT05924425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized in the control group will receive the placebo every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
Study NCT05924425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: A full-night polysomnography recording with blood pressure and heart rate monitoring will be performed at night in the Sleep Laboratory from 11 p.m. to 7 a.m. at baseline (before the randomization) and at the end of each period (Period A/M1, Period B/M2). The recording procedure consists of an electroencephalogram, two electrooculograms, an electromyogram, an electrocardiogram, and a videographic recording. This examination is painless (the sensors are glued to the skin for the duration of the recording). The advantages of this video-polysomnography are based on the evaluation of sleep architecture, micro-arousals, respiratory events and nocturnal motor behavior.
Study NCT05924425 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Polysomnography
Description: A full-night polysomnography recording with blood pressure and heart rate monitoring will be performed at night in the Sleep Laboratory from 11 p.m. to 7 a.m. at baseline (before the randomization) and at the end of each period (Period A/M1, Period B/M2). The recording procedure consists of an electroencephalogram, two electrooculograms, an electromyogram, an electrocardiogram, and a videographic recording. This examination is painless (the sensors are glued to the skin for the duration of the recording). The advantages of this video-polysomnography are based on the evaluation of sleep architecture, micro-arousals, respiratory events and nocturnal motor behavior.
Study NCT05924425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: A full neuropsychological assessment will be performed at inclusion, M1, M2
Study NCT05924425 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neuropsychological assessment
Description: A full neuropsychological assessment will be performed at inclusion, M1, M2
Study NCT05924425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires on sleep and behavioural problems
Description: Questionnaires on sleep and behavioural problems will be performed at inclusion, M1, M2
Study NCT05924425 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires on sleep and behavioural problems
Description: Questionnaires on sleep and behavioural problems will be performed at inclusion, M1, M2
Study NCT05924425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Actimetrics
Description: Measurement of actimetrics for seven days in average (with a minimum of three nights required) prior to the inclusion visit, M1 visit and M2 visit.
Study NCT05924425 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Actimetrics
Description: Measurement of actimetrics for seven days in average (with a minimum of three nights required) prior to the inclusion visit, M1 visit and M2 visit.
Study NCT05924425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24-hour Ambulatory Blood Pressure Monitoring (ABPM
Description: Evaluation of the 24-hour hemodynamic profile of a patient by multiple and regular blood pressure and heart rate measurements. The ABP will be monitored at inclusion, M1 and M2
Study NCT05924425 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 24-hour Ambulatory Blood Pressure Monitoring (ABPM
Description: Evaluation of the 24-hour hemodynamic profile of a patient by multiple and regular blood pressure and heart rate measurements. The ABP will be monitored at inclusion, M1 and M2
Study NCT05924425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker assay
Description: Determination of AD biomarkers (Aβ42, Aβ40, Tau, P-Tau, neurofilament) and proinflammatory cytokines (TNFa, IL6) in serum and cerebrospinal fluid (CSF) and dosage of Orexin-A/hypocretin-1 in the CSF
Study NCT05924425 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Biomarker assay
Description: Determination of AD biomarkers (Aβ42, Aβ40, Tau, P-Tau, neurofilament) and proinflammatory cytokines (TNFa, IL6) in serum and cerebrospinal fluid (CSF) and dosage of Orexin-A/hypocretin-1 in the CSF
Study NCT06045455 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multimodal brain CT
Description: Multimodal brain CT includes NCCT, CTP, and CTA
Study NCT06045455 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: MRI examination will be performed between the 3rd and 7th day after the admission to the hospital
Study NCT05684575 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phone satisfaction questionnaire
Description: Evaluation of the outcome of Covid-19 patients discharged home on oxygen therapy
Study NCT05902273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hemodynamic monitoring
Description: Baxter Starling Monitor for measuring cardiac output and systemic vascular resistance (SVRI) which is using bioreactance technology. We need to place four electrodes on chest wall (upper left, upper right, down left, down right) and input monitor demographic parameters. Also enter mean arterial pressure (MAP) for calculating SVRI so we input MAP every minute.Patient bed set as 45 degree head elevated and legs 0 degree. Just after start measuring, monitor needs to synchronize itself for patient. After synchronisation we start fluid challenge with passive leg raising option. This test has two stages. First stage calculating baseline parameters which takes 3 minutes and second stage is measuring difference with fluid challenge which also takes 3 minutes. At the end of first stage monitor shows to perform passive leg raise and we perform trendelenburg maneuver till head comes to 0 degree. After second stage measurement has finished.
Study NCT05902273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: resistive index
Description: We use ultrasonography at the same time with cardiac output monitor in both stages. First we determine the location of radial artery at wrist snuffbox at 1.5 centimeters depth with linear probe and confirm pulsatile flow with color mode. In Starling's baseline stage we measure and calculate resistive index with doppler P-mode in triplex setting 3 times. When received 3 same result successively we noted as SBRI-1. Second measurement is initiated at last 30 seconds of passive leg raising as described before and we noted our measurement as SBRI-2
Study NCT05902273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pleth variability index
Description: During all stages Masimo Rad-87 rainbow probe is placed patients index or middle finger and we note PVI-1 and PVI-2 at the same time with SBRI-1 and SBRI-2
Study NCT05021874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Four different physiotherapy treatment
Description: Four different physiotherapy treatment will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 10th day of therapy, it will be measured ROM.
Study NCT04900350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: Subjects receive AK117 intravenously.
Study NCT04900350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subjects receive Azacitidine subcutaneously.
Study NCT03443622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-43 Oral Solution
Description: SC-43 Oral Solution has drug substance of 1-\[4-chloro-3(trifluoromethyl)phenyl-3-\[3-(4-cyanophenoxy)\] urea, or SC-43. SC-43 inhibits tumor growth through the activation of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and the repression of p-STAT3 signalings. As a result of STAT3 inhibition by SC-43 treatment, decreased cell viability and enhanced apoptosis have been observed in cancer cells. The anti-tumor activity of SC-43 was also investigated in a variety of xenograft tumor models. Administration of SC-43 provides the tumor-bearing animals survival benefits, including the reduction of tumor volume and prolonged lifespan. SC-43 has been proposed to be evaluated as an anticancer therapeutic in in subjects with refractory solid tumors in the phase I trial.
Study NCT04615130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitation, exercise training
Study NCT05806944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS followed by Sham TMS
Description: double blinded crossover schedule in which participants will undergo TMS and assessment in one visit, followed by sham-TMS and assessment the next visit.
Study NCT05083936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FET
Description: Imaging evaluation using LAT1/4F2hc substrate overexpressed in brain tumor
Study NCT06143345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training and eucaloric diet
Description: Intervention participants will complete 24 supervised high-intensity interval training (HIIT) sessions over 8 weeks, with 3 sessions per week on alternate days. Each HIIT session will consist of a 5-minute warm-up, followed by an interval-based workout phase that includes steady up-tempo cadences, sprints, and climbs, interspersed with recovery periods. The session will conclude with a 5-minute cooldown. The workout sessions will initially last 20 minutes and will progressively increase in time based on participants\&amp;#39; tolerance and instructor recommendations. Intensity will start at 75% of estimated maximal heart rate reserve and will increase by 5% weekly, as tolerated and/or deemed necessary by the instructor, over the 8-week intervention period. Participants will receive instructions to maintain a eucaloric diet throughout the study.
Study NCT06143345 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No intense physical activity and eucaloric diet
Description: Control participants will be instructed to refrain from engaging in intense physical activities during the study period. They will also receive instructions to maintain a eucaloric diet throughout the study.
Study NCT06143345 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring (CGM) (Dexcom G6 Pro CGM sensor)
Description: The continuous glucose monitoring (CGM) system comprises a sensor, a transmitter, and a receiver. The sensor measures interstitial fluid glucose levels every 5 minutes, and the transmitter wirelessly sends this glucose data to the receiver. Both intervention and control participants will wear the CGM device in a blinded mode for 10 days before starting the intervention, throughout the 8-week intervention period, and for 10 days post-intervention.
Study NCT06143345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) (Dexcom G6 Pro CGM sensor)
Description: The continuous glucose monitoring (CGM) system comprises a sensor, a transmitter, and a receiver. The sensor measures interstitial fluid glucose levels every 5 minutes, and the transmitter wirelessly sends this glucose data to the receiver. Both intervention and control participants will wear the CGM device in a blinded mode for 10 days before starting the intervention, throughout the 8-week intervention period, and for 10 days post-intervention.
Study NCT05806944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TMS followed by TMS
Description: double blinded crossover schedule in which participants will undergo sham TMS and assessment in one visit, followed by TMS and assessment the next visit.
Study NCT04717362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natesto Nasal Product
Description: Nasally administered exogenous 4.5% testosterone gel, administered from a non-pressurized, manual pump dispenser equipped with a specialized nasal applicator which administers 125uL (5.5mg of testosterone).
Study NCT05887271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low calorie meal replacement plan
Description: Meal replacement diet containing \~850 kcal/day (40% protein, 50% carbohydrate, 10% fat) supplied by Counterweight® (www.counterweight.org).The meal replacement plan will comprise of 3-4 meal packs/day (to equate to 850 kcal) with sweet and savoury options, and an allowance of 100ml semi-skimmed milk or a non-dairy alternative.
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy
Description: CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue. Cardiac 31P magnetic resonance spectroscopy imaging to assess cardiac muscle energetics according to a standardised operating procedure
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy
Description: CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue. Cardiac 31P magnetic resonance spectroscopy imaging to assess cardiac muscle energetics according to a standardised operating procedure
Study NCT04995406 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ISIT-TB prototype
Description: Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour
Study NCT04148716 — intervention group
Intervention type: PROCEDURE
Intervention: additional biopsies
Description: additional biopsies during a fibroscopy planned in the care
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transthoracic echocardiography
Description: Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Description: Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: Collection of blood samples from each participant to characterise the participant's health status and fibroinflammatory markers.
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Collection of blood samples from each participant to characterise the participant's health status and fibroinflammatory markers.
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiogram
Description: An ECG will be obtained to assess for baseline rhythm.
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: An ECG will be obtained to assess for baseline rhythm.
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometery
Description: Accelerometer (GeneActiv) measured daily activity levels continuously for 7 consecutive days.
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Accelerometery
Description: Accelerometer (GeneActiv) measured daily activity levels continuously for 7 consecutive days.
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 6 minute walk test (6MWT)
Description: Supervised 6MWT will be performed with symptom assessment using dyspnoea scale (Borg's).
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6 minute walk test (6MWT)
Description: Supervised 6MWT will be performed with symptom assessment using dyspnoea scale (Borg's).
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Skeletal muscle strength using handgrip strength and quadriceps (Cybex dynamometer)
Description: Skeletal muscle strength will be measured using a cybex dynamometer.
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skeletal muscle strength using handgrip strength and quadriceps (Cybex dynamometer)
Description: Skeletal muscle strength will be measured using a cybex dynamometer.
Study NCT05887271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of quality of life and heart failure symptoms
Description: Quality of life and HF symptoms will be assessed using the Minnesota Living with Heart Failure (MLWHF) questionnaire, which is used as a standardised measure of self-reported health status, and HF symptoms and is considered to have a good discriminatory power and validity
Study NCT05887271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of quality of life and heart failure symptoms
Description: Quality of life and HF symptoms will be assessed using the Minnesota Living with Heart Failure (MLWHF) questionnaire, which is used as a standardised measure of self-reported health status, and HF symptoms and is considered to have a good discriminatory power and validity
Study NCT05887271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of sarcopenia
Description: Participants will be assessed for presence of sarcopenia using the Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F) questionnaire. It is a robust tool for diagnosis of sarcopenia and prediction poor physical function, with excellent specificity in multimorbid individuals.
Study NCT05887271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of sarcopenia
Description: Participants will be assessed for presence of sarcopenia using the Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F) questionnaire. It is a robust tool for diagnosis of sarcopenia and prediction poor physical function, with excellent specificity in multimorbid individuals.
Study NCT05887271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of frailty
Description: Frailty will be assessed using the Edmonton Frail Scale (EFS). The EFS is a multidimensional frailty assessment which assesses multiple domains of frailty including functional independence, social support, cognition, medication use, and mood.
Study NCT05887271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of frailty
Description: Frailty will be assessed using the Edmonton Frail Scale (EFS). The EFS is a multidimensional frailty assessment which assesses multiple domains of frailty including functional independence, social support, cognition, medication use, and mood.